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Abstract
Objective Several reports found that obesity was associ-
ated with prostate cancer (PC) aggressiveness among men
treated with radical prostatectomy or radiotherapy. Studies
concerning this issue have basically relied on body mass
index (BMI), as a marker for general obesity. Because vis-
ceral fat is the most metabolic active fat, we sought to eval-
uate if periprostatic fat measured on a computed
tomography (CT) is a better marker than BMI to predict PC
aggressiveness in a Dutch population who underwent
brachytherapy for localized PC.
Patients and methods Of the 902 patients who underwent
brachytherapy, 725 CT scans were available. Subcutaneous
fat thickness (CFT), periprostatic fat area (cm2) and fat-
density (%) were determined on the CT scan. Patients were
stratiWed into three groups: <25, 25–75 and >75 percentile
of the fat-density. Associations between the three fat-
density subgroups and BMI and PC aggressiveness were
examined.
Results 237 patients were classiWed as having normal
weight (37.2%), 320 as overweight (50.2%) and 80 as
obese (12.6%). There was a strong signiWcant association
between BMI and fat-density and CFT. The strongest corre-
lation was seen between BMI and CFT (Pearson r
coeYcient = 0.71). Logistic regression analysis revealed no
statistically signiWcant association between the diVerent fat
measurements and the risk of having a high-risk disease.
Conclusions Periprostatic fat and fat-density as measured
with CT were not correlated with PC aggressiveness in
patients receiving brachytherapy. However, 31% of the
patients with a normal BMI had a fat-density of >75 per-
centile of the periprostatic fat-density.
Keywords Obesity · Visceral fat · Prostate cancer · 
Body mass index (BMI) · Brachytherapy
Introduction
Obesity and prostate cancer (PC) are two major health con-
cerns. On one hand, obesity is a rapidly growing worldwide
epidemic and it increases the risk of several chronic dis-
eases and certain cancers [1, 2]. On the other hand, PC is
diagnosed more often in the prostate-speciWc antigen (PSA)
era and the disease is often diagnosed at a localized stage
suitable for curative treatment [3].
The relationship between obesity and PC is debated,
with studies Wnding an inverse, a linear correlation with PC,
or no relation at all [4–6]. However, several studies found a
link between obesity and disease aggressiveness [7–9].
Recently, the classical perception of adipose tissue as a
storage place of fatty acids has been replaced by the notion
that adipose tissue produces a large number of hormones
and cytokines, e.g., tumour necrosis factor-, interleukin-6,
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leptin and adiponectin [10]. The exact role of these cyto-
kines in prostate carcinogenesis, however, is not known.
Most of the studies that investigated the role of obesity on
PC used body mass index (BMI, the weight in kilograms
divided by the squared height in meters) as a marker of gen-
eral obesity. Although there is a strong correlation between
BMI and waist-circumference (WCF), the most metabolic
active fat is the abdominal visceral fat and a better way to
measure this is by waist-hip ratio or WCF. Therefore, WCF
as an indicator of abdominal fat may be a better predictor
for PC risk than BMI alone, especially in men with a low
BMI. Computed tomography (CT) is another technique
which measures visceral fat even more accurately [11, 12].
The aim of this study was to investigate whether peri-
prostatic fat, measured on a CT, is a better marker for PC
aggressiveness in patients who underwent brachytherapy
for localized PC compared to BMI. We also evaluated the
relation between BMI and diVerent fat measurements. To
the best of our knowledge such a study has never been per-
formed.
Patients and methods
Patients
Between April 2004 and August 2008, 902 patients with
biopsy-proven localized PC (stage cT1 or cT2) were
treated with transrectal ultrasonography guided transperi-
neal permanent mono brachytherapy at the department of
Radiotherapy, University Medical Center Utrecht, The
Netherlands. Due to the very short follow-up of this cohort
of men we only focused on PC baseline characteristics.
Patients underwent clinical staging by medical history,
digital rectal examination and serum PSA measurement.
Bone scans were obtained and pelvic lymph node dissec-
tion was performed when clinically indicated. A CT was
performed 1 day after the brachytherapy to determine spe-
ciWc dose constraints. The CT was not performed in 153
patients and in 24 patients the quality of the CT was poor
due to hip prostheses. This resulted in a study population
of 725 men.
Because diVerent risk classiWcations are used in the liter-
ature we decided to use two diVerent risk classiWcations,
one according to Ash et al. [13] and the other according to
D’Amico et al. [14]. Tumour stage was described according
to the 2002, TNM, American Joint Committee on Cancer
system.
Fat measurement
Preoperative height and weight data were collected retro-
spectively by reviewing anaesthesia records. The BMI
(kg/m2) was calculated and stratiWed into three groups
according to the WHO, i.e. normal weight (<25), over-
weight (25–30) and obese (¸30). Only one patient had a
BMI value of <18.5 kg/m2, this patient was included in the
normal weight group. The CT’s were acquired on a single
slice CT (Aura, Philips Medical Systems, Best, The Nether-
lands), and had an in-plane slice resolution of
0.49 £ 0.49 mm with a slice thickness of 3 mm. We used
an in-house developed software tool for delineation of the
pelvic fat region and the measurement of the subcutaneous
fat thickness (CFT, see Fig. 1) [15].
Because there are no comparable studies available we
chose to delineate along established lines (see Fig. 1). The
fat contained within the delineated contours of the CT, is
segmented by thresholding on the HounsWeld Units (HU).
We diVerentiated between fat (¡190 to ¡30 HU), air
(<¡500 HU) and other soft tissue types [16]. Since the
delineated contours did not contain bony structures, we did
Fig. 1 Images demonstrate our method for determining visceral fat
distribution and subcutaneous fat thickness on a CT scan. a Transverse
section is made at the level of the caput femoris and greater trochanter
of the femur. The red line, outlines the total contour area (cm2), in
which attenuation is measured. The line is drawn at the back side of
the pubic bone, lateral border of obturatorius internus muscle, anterior
side of the gluteus maximus muscle and coccyx bone. Within the
region of interest the periprostatic fat area (cm2) and the fat-density (%)
was calculated. b Transverse section is made at the level of superior
pubic ramus. The red line outlines the subcutaneous fat thickness by
which the distance between the skin and pubic bone is measured. (cm)World J Urol (2010) 28:699–704 701
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not include a threshold for segmenting the bones separately.
The total contour area (cm2) was calculated by the total
number of voxels within the contour minus the number of
air voxels and the periprostatic fat area (cm2) by just count-
ing ‘fat’ voxels within the total contour area. The fat-den-
sity (%) was calculated by dividing periprostatic fat by the
total contour area.
Patients were stratiWed into three groups: <25 percentile
(group 1), between 25 and 75 percentile (group 2) and >75
percentile (group 3) of the fat-density.
Statistical analysis
Associations between the predeWned three fat-density sub-
groups and clinical or pathological characteristics were
examined by Chi-square tests in case of categorical charac-
teristics and Kruskal–Wallis tests in case of continuous
characteristics. The Pearson correlation coeYcient was
used to quantify correlations between BMI and the diVerent
fat measurements. Binary logistic regression analyses were
performed to evaluate the independent eVect of each vari-
able on the risk of having high-risk disease versus low or
intermediate risk (according to Ash et al. [13] and D’Amico
et al. [14]).
DiVerences were considered to be statistically signiWcant
if p < 0.05. Data were analysed using SPSS for Windows
(version 15.0).
Results
The median age (range), BMI and fat-density at the time of
brachytherapy was 66 years (45–81), 25.8 kg/m2 (17.6–
56.8) and 31.8% (10.0–52.2), respectively. In 88 (12%)
patients the BMI was not available. In all, 237 patients were
classiWed as having normal weight (37.2%), 320 as over-
weight (50.2%) and 80 as obese (12.6%). Table 1 summa-
rizes the clinical and pathological characteristics of the
study population stratiWed by fat-density.
Patients in group 3 were signiWcantly older. The median
prostate volume was statistically diVerent between the three
groups but the diVerences were not clinically relevant. A
clear signiWcant association was seen between the fat-den-
sity groups and BMI, CFT and periprostatic fat. Figure 2
shows the correlation between BMI and the diVerent fat
measurements. The strongest correlation was seen between
BMI and CFT (Pearson r coeYcient = 0.71, p <0 . 0 0 1 ) .
Logistic regression analysis revealed no statistically sig-
niWcant association between the diVerent fat measurements
and the risk of having high-risk disease (Table 2). Only age
was signiWcantly associated with increased risk of having a
high-risk disease, however in the multivariable analysis
(data not shown) this signiWcance disappeared.
Discussion
The urologist and radiation oncologist will be confronted
more frequently with obese patients having a localized PC.
Although the association between obesity and the risk of
PC risk is controversial [4, 17, 18], a stronger link between
obesity and increased risk for higher pathologic grade and
higher rates of biochemical recurrence (BCR) compared
with normal weight patients was seen in several studies [9,
19, 20]. Of note, all these studies were done in the USA.
We conducted a study in The Netherlands where we evalu-
ated 1,302 patients who underwent a radical prostatectomy.
In that study BMI did not appear to have any prognostic
value for BCR or worse pathologic features [21]. Same
conclusions were drawn by another European study by
PWtzenmaier et al. [22]. In contrast with the USA, where
30% of the population is obese, only 9% to 14% of the
European population was obese [23, 24]. Thereby, obese
patients are less obese than the obese men in the USA and a
relatively large proportion of the USA population consists
of Afro-Americans who are more prone to be obese and
more frequently have aggressive tumours compared with
white men.
A question which may rise: are we measuring obesity on
the right way? In most studies investigating obesity in rela-
tion to prostate aggressiveness and BCR, BMI is used as a
criterion for general obesity. The most metabolic active fat
however, is the abdominal visceral fat. WCF, as an indica-
tor of abdominal obesity may be a better predictor of risk of
more aggressive PC than BMI, especially in individuals
with a lower BMI. Visceral fat is the most metabolic active
fat and produce diVerent kind of adipokines. Obesity is
associated with increased levels of several adipokines and
studies reported a link between the level of adipokines and
aggressive PC [25–27].
A large study by the European Prospective Investigation
into Cancer and Nutrition group concluded that once gen-
eral obesity was adjusted for abdominal fat distribution it
was positively associated with the risk of death. This asso-
ciation tended to be stronger among participants with a
lower BMI [28]. In a large prospective cohort of 148,372
men, Pischon et al. [29] found that higher WCF was associ-
ated with increased risk of advanced PC and high-grade PC
among individuals with lower BMI. The relative risk of
advanced PC was 1.06 (95% CI 1.01–1.10) per 5-cm-larger
WCF. Same conclusions were drawn in a prospective
Swedish study [30]. These data suggest that especially
abdominal adiposity may be associated with an increased
risk of advanced PC and WCF is a better way to measure
obesity.
Visceral fat can aVect both the lean and obese and is
more metabolically active than subcutaneous fat. By mea-
suring the WCF the discrepancy between thin outside702 World J Urol (2010) 28:699–704
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(subcutaneous fat) and thick inside (visceral fat) cannot be
made. A CT scan can distinguish between these two “lay-
ers”. In our study we measured the visceral and subcutane-
ous fat on a CT to identify if one of these parameters is a
better marker for tumour characteristics compared with
BMI. Possible explanations for the lack of this correlation
can be, Wrst, there has been less enthusiasm for the use of
brachytherapy in men with high-risk disease. These patients
might be very well selected which can be an explanation for
these negative Wndings. Second, the fat measurement was
performed on one cross-sectional scan. Theoretically the
accuracy of the fat measurement could be improved by
measuring the fat content on more cross-sectional scans
(volume measurement). However, in this study the selec-
tion bias of the brachytherapy patients is probable more
important than the technique of fat measurement. Third, it
is possible that the fat around the intra-abdominal organs
are more metabolic active than the periprostatic fat. It
would be interesting to measure the fat around the intra-
abdominal organs. However, it was not possible to measure
the intra-abdominal fat distribution and body circumference
at the level of the umbilicus. Fourth, it would be very inter-
esting to correlate the BMI and fat density with clinical out-
come like BCR or disease speciWc survival instead of pre-
treatment Gleason score, because these are better prognos-
tic markers for PC aggressiveness. However, in this study
the follow-up was much too short (mean < 20 months) to
evaluate these outcomes.
Our analysis showed a correlation between BMI and
CFT and periprostatic fat-density. The correlation between
Table 1 Baseline 
characteristics
Group 1
N =1 8 1
<25 percentile
Group 2
N =3 6 3
25–75 percentile
Group 3
N =1 8 1
>75 percentile
p value
Median (IQR)
Age, years 64.0 (59.0–68.0) 66.0 (61.0–70.0) 68.0 (63.0–71.0) <0.001a
Follow up, months 18.0 (11.0–30.5) 16.5 (11.0–28.8) 18.0 (11.0–29.0) 0.97a
Prostate volume, cm3 37.0 (30.0–44.0) 34.3 (28.0–41.0) 34.0 (27.8–40.0) 0.02a
Initial PSA, ng/ml 8.4 (6.3–12.2) 8.5 (6.3–11.7) 9.0 (6.9–12.5) 0.20a
BMI, kg/m2 24.5 (22.8–26.4) 26.0 (24.6–27.8) 26.8 (24.8–29.4) <0.001a
Total periprostatic fat, cm2 23.7 (19.3–25.9) 31.3 (28.0–34.5) 40.5 (36.9–43.5) <0.001a
Fat density, % 24.0 (21.3–26.0) 31.8 (29.2–33.9) 38.5 (37.1–40.9)
Subcutaneous fat, cm 3.9 (3.2–4.7) 4.7 (3.9–5.5) 5.1 (4.1–6.1) <0.001a
N (%)
WHO-classiWcation
Normal weight 88 (57.9) 109 (33.5) 40 (25.0) <0.001b
Overweight 60 (39.5) 175 (53.8) 85 (47.0)
Obesity 4 (2.6) 41 (12.6) 35 (19.3)
Clinical stage
T1 112 (61.9) 252 (69.4) 119 (66.1) 0.21b
T2 69 (38.1) 111 (30.6) 61 (33.9)
Grade
Low 111 (61.3) 231 (64.2) 114 (64.0) 0.46b
Intermediate 70 (38.7) 129 (35.8) 64 (36.0)
Ash risk group
Low 69 (38.1) 141 (39.2) 67 (37.4) 0.96b
Intermediate 76 (42.0) 154 (42.8) 75 (41.9)
High 36 (19.9) 65 (18.1) 37 (20.7)
D’Amico risk group
Low 72 (39.8) 145 (39.9) 70 (38.7) 0.40b
Intermediate 99 (54.7) 200 (55.1) 95 (52.5)
High 10 (5.5) 14 (3.9) 12 (6.6)
Lymph node dissection
Yes 7 (3.9) 5 (1.4) 3 (1.7) 0.14b
No 174 (96.1) 358 (98.6) 178 (98.3)
Patients were stratiWed by fat 
density
IQR interquartile range
a Kruskal–Wallis-test
b 2-TestWorld J Urol (2010) 28:699–704 703
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BMI and CFT was much stronger than BMI and fat density.
Interestingly, 31% of the patients with a normal BMI had a
fat-density >75 percentile, compared with only 10% of the
obese patients who had a fat-density <25 percentile of the
fat-density. Thus, measurements on the outside of the body
(BMI) do not always reXect the inner fat distribution mea-
sured on a CT scan. It is attractive to speculate that when
this study was performed in a group of patients with more
high-grade tumours, e.g. a group treated with external
radiotherapy, these parameters could be a better prognostic
marker for tumour characteristics than BMI, especially in
patients with a low BMI. However, further studies are
needed to identify the real value of these fat measurements
on CT as correlates with PC aggressiveness.
Conclusion
Periprostatic fat and fat-density were not of any value to
predict PC aggressiveness in patients receiving brachyther-
apy. However, 31% of the patients with a normal BMI had
a fat-density of >75 percentile of the periprostatic fat-den-
sity. More studies, including patients who have more
aggressive PC, are needed to identify the true value of fat
measurement on a CT as a correlate of PC aggressiveness
and/or predictor of treatment failure.
Fig. 2 Correlation between body mass index and diVerent fat
measurements. The linear regressive line is shown with 95% CI. The
vertical line represents the median
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Table 2 Univariable logistic regression analysis of factors predicting
high-risk disease
Variable Odds ratio (95% CI) p value
According to ash
Age 1.07 (1.03–1.11) <0.001
Prostate volume 1.00 (0.98–1.02) 0.68
BMI (continuous) 0.97 (0.92–1.03) 0.37
BMI
<25 kg/m2 1
25–30 kg/m2 0.80 (0.53–1.21) 0.29
¸30 kg/m2 0.51 (0.24–1.06) 0.07
Fat density (continuous) 1.00 (0.97–1.03) 0.94
Fat density
Group 1 1
Group 2 0.89 (0.56–1.40) 0.61
Group 3 1.05 (0.63–1.76) 0.85
Subcutaneous fat thickness 0.96 (0.85–1.10) 0.56
Periprostatic fat area 1.00 (0.976–1.02) 0.76
According to D’Amico
Age 1.06 (1.00–1.13) 0.06
Prostate volume 1.01 (0.97–1.05) 0.57
BMI (continuous) 0.89 (0.79–1.01) 0.09
BMI
<25 kg/m2 1
25–30 kg/m2 0.63 (0.29–1.34) 0.23
¸30 kg/m2 0.40 (0.86–1.73) 0.21
Fat density (continuous) 1.00 (0.95–1.06) 0.94
Fat density
Group 1 1
Group 2 0.69 (0.30–1.59) 0.39
Group 3 1.24 (0.52–2.96) 0.62
Subcutaneous fat thickness 0.80 (0.95–1.05) 0.11
Periprostatic fat area 1.00 (0.96–1.05) 0.93704 World J Urol (2010) 28:699–704
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